| abstract |
Isolated human monoclonal antibodies that bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Human antibodies can be produced by transgenic mice that can produce human monoclonal antibodies of various isotypes by transfectoma or non-human transgenic animals such as V-D-J recombination and isotype conversion. Also disclosed are pharmaceutical compositions comprising human antibodies, non-human transgenic animals and hybridomas producing human antibodies, and methods of treatment and diagnostics using human antibodies. |